BACKGROUND/AIMS: The impact of nebivolol therapy on the renal proximal tubular cell (PTC) structure and function was investigated in a transgenic (TG) rodent model of hypertension and the cardiometabolic syndrome. The TG Ren2 rat develops nephropathy with proteinuria, increased renal angiotensin II levels and oxidative stress, and PTC remodeling. Nebivolol, a beta(1)-antagonist, has recently been shown to reduce albuminuria, in part, through reductions in renal oxidative stress. Accordingly, we hypothesized that nebivolol therapy would attenuate PTC damage and tubulointerstitial fibrosis. METHODS: Young Ren2 (R2-N) and SD (SD-N) rats were treated with nebivolol (10 mg/kg/day) or vehicle (R2-C; SD-C) for 3 weeks. PTC structure and function were tested using transmission electron microscopy and functional measurements. RESULTS: Nebivolol treatment decreased urinary N-acetyl-beta-D-glucosaminidase, tubulointerstitial ultrastructural remodeling and fibrosis, NADPH oxidase activity, 3-nitrotyrosine levels, and increased megalin and lysosomal-associated membrane protein-2 immunostaining in PTCs. Ultrastructural abnormalities that were improved with therapy included altered canalicular structure, reduced endosomes/lysosomes and PTC vacuoles, basement membrane thickening, and mitochondrial remodeling/fragmentation. CONCLUSION: These observations support the notion that nebivolol may improve PTC reabsorption of albumin and other glomerular filtered small molecular weight proteins in association with the attenuation of oxidative stress, tubulointerstitial injury and fibrosis in this rat model of metabolic kidney disease. 2010 S. Karger AG, Basel.
BACKGROUND/AIMS: The impact of nebivolol therapy on the renal proximal tubular cell (PTC) structure and function was investigated in a transgenic (TG) rodent model of hypertension and the cardiometabolic syndrome. The TG Ren2 rat develops nephropathy with proteinuria, increased renal angiotensin II levels and oxidative stress, and PTC remodeling. Nebivolol, a beta(1)-antagonist, has recently been shown to reduce albuminuria, in part, through reductions in renal oxidative stress. Accordingly, we hypothesized that nebivolol therapy would attenuate PTC damage and tubulointerstitial fibrosis. METHODS: Young Ren2 (R2-N) and SD (SD-N) rats were treated with nebivolol (10 mg/kg/day) or vehicle (R2-C; SD-C) for 3 weeks. PTC structure and function were tested using transmission electron microscopy and functional measurements. RESULTS:Nebivolol treatment decreased urinary N-acetyl-beta-D-glucosaminidase, tubulointerstitial ultrastructural remodeling and fibrosis, NADPH oxidase activity, 3-nitrotyrosine levels, and increased megalin and lysosomal-associated membrane protein-2 immunostaining in PTCs. Ultrastructural abnormalities that were improved with therapy included altered canalicular structure, reduced endosomes/lysosomes and PTC vacuoles, basement membrane thickening, and mitochondrial remodeling/fragmentation. CONCLUSION: These observations support the notion that nebivolol may improve PTC reabsorption of albumin and other glomerular filtered small molecular weight proteins in association with the attenuation of oxidative stress, tubulointerstitial injury and fibrosis in this rat model of metabolic kidney disease. 2010 S. Karger AG, Basel.
Authors: Adam T Whaley-Connell; Nazif A Chowdhury; Melvin R Hayden; Craig S Stump; Javad Habibi; Charles E Wiedmeyer; Patricia E Gallagher; E Ann Tallant; Shawna A Cooper; C Daniel Link; Carlos Ferrario; James R Sowers Journal: Am J Physiol Renal Physiol Date: 2006-06-20
Authors: Melvin R Hayden; Nazif A Chowdhury; Shawna A Cooper; Adam Whaley-Connell; Javad Habibi; Lauren Witte; Charles Wiedmeyer; Camila Margarita Manrique; Guido Lastra; Carlos Ferrario; Craig Stump; James R Sowers Journal: Am J Physiol Renal Physiol Date: 2006-10-10
Authors: Mahboob Rahman; Sara Pressel; Barry R Davis; Chuke Nwachuku; Jackson T Wright; Paul K Whelton; Joshua Barzilay; Vecihi Batuman; John H Eckfeldt; Michael A Farber; Stanley Franklin; Mario Henriquez; Nelson Kopyt; Gail T Louis; Mohammad Saklayen; Carole Stanford; Candace Walworth; Harry Ward; Thomas Wiegmann Journal: Ann Intern Med Date: 2006-02-07 Impact factor: 25.391
Authors: Andrea Hartner; Markus Porst; Bernd Klanke; Nada Cordasic; Roland Veelken; Karl F Hilgers Journal: Nephrol Dial Transplant Date: 2006-03-07 Impact factor: 5.992
Authors: Jasmina Varagic; Sarfaraz Ahmad; K Bridget Brosnihan; Javad Habibi; Roger D Tilmon; James R Sowers; Carlos M Ferrario Journal: Am J Nephrol Date: 2010-11-02 Impact factor: 3.754
Authors: Adam Whaley-Connell; Javad Habibi; Zachary Panfili; Melvin R Hayden; Sarika Bagree; Ravi Nistala; Safwan Hyder; Bennett Krueger; Vincent Demarco; Lakshmi Pulakat; Carlos M Ferrario; Alan Parrish; James R Sowers Journal: Am J Nephrol Date: 2011-06-29 Impact factor: 3.754
Authors: Javad Habibi; Melvin R Hayden; James R Sowers; Lakshmi Pulakat; Roger D Tilmon; Camila Manrique; Guido Lastra; Vincent G Demarco; Adam Whaley-Connell Journal: Endocrinology Date: 2010-12-22 Impact factor: 4.736
Authors: Melvin R Hayden; Javad Habibi; Tejaswini Joginpally; Poorna R Karuparthi; James R Sowers Journal: Cardiorenal Med Date: 2012-01-27 Impact factor: 2.041
Authors: Adam Whaley-Connell; Lakshmi Pulakat; Vincent G DeMarco; Melvin R Hayden; Javad Habibi; Erik J Henriksen; James R Sowers Journal: Cardiorenal Med Date: 2011-01-17 Impact factor: 2.041
Authors: Felipe Cabezas; Jonathan Lagos; Carlos Céspedes; Carlos P Vio; Miguel Bronfman; María-Paz Marzolo Journal: PLoS One Date: 2011-02-02 Impact factor: 3.240